Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Integra LifeSciences in its filing.
Tagged under the XBRL concept us-gaap:OtherDepreciationAndAmortization.
The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:03 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000917520-26-000058
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| OPERATING ACTIVITIES: | ||
| Net loss | $(134) | $(509,366) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||
| Depreciation and amortization | 76,565 | 74,880 |
| Non-cash impairment charges | — | 511,365 |
| Deferred income tax provision (benefit) | (3,007) | (46,663) |
| Share-based compensation | 11,009 | 7,165 |
| Amortization of debt issuance costs and expenses associated with debt refinancing | 2,015 | 3,275 |
Item 1. Financial Statements
FAQ
- What is Integra LifeSciences's D&A?
- Integra LifeSciences (IART) reported D&A of $38.14M in Q2 2026.
- How has Integra LifeSciences's D&A changed year-over-year?
- Integra LifeSciences's D&A increased by 1.2% year-over-year, from $37.69M to $38.14M.
- What is the long-term trend for Integra LifeSciences's D&A?
- Over 4 years (2021 to 2025), Integra LifeSciences's D&A has grown at a 6.1% compound annual growth rate (CAGR), from $119.84M to $151.83M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Integra LifeSciences's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude